Mekhman mamedov email4/7/2023 No significant dynamic changes in ceramides and ceramide risk against the background of statin therapy were observed, however, PCSK9 inhibitor added to therapy reduced the Cer 16:0/24:0 ratio. It has been shown, that decreased sphingomyelin levels are associated with statin therapy and correlate with decreased levels of LDL-C. In group 3, total cholesterol decreased by 36.2%, and LDL-C (p = 0.018) decreased by 60.1% compared to baseline (ALDL-C = -2.67 ± 3.12) the elevated levels of ceramide Cer 22:1 (p = 0.028) were observed. The level of Cer 22:1 significantly increased (p = 0.028). In group 2, the significantly decreased levels of total cholesterol (p = 0.028), LDL (p = 0.043), sphingomyelins SM 18:1, SM 24:1 and SM 26:1, and ceramide Cer 16:1 (p = 0.028) were observed. There were no significant changes in the levels of total cholesterol, LDL-C, HDL-C, and triglycerides. In group 1, the decreased levels of ceramide Cer 14:1 (p = 0.046) and sphingomyelins SM 22:1, SM 22:0, SM 24:0 (p = 0.028) were observed. Sphingolipid levels were assessed by mass spectrometry. A total of 18 patients were enrolled (the average age was 53 ± 6.7 years): in group 1, six patients received starting statin doses group 2 included six patients, who failed to achieve LDL target levels against the background of treatment with starting statin doses, and received escalated statin doses seven patients in group 3 failed to achieve LDL target levels against the background of treatment with maximum tolerated doses of statins and ezetimibe, and received alirocumab. The study was aimed to assess the dynamic changes in cholesterol, high- and low-density lipoproteins (HDL and LDL), triglycerides, and sphingolipids against the background of lipid-lowering therapy in patients with premature coronary artery disease, atherosclerosis and hypercholesterolemia. However, we have no knowledge of changes in other plasma lipids upon treatment. Lipid-lowering drugs affect standard lipoproteins. Emanuel, Moscow, RussiaĤ Lomonosov Moscow State University, Moscow, Russia Rogozhina AA1'2, Alessenko AV3, Kurochkin IN3, Minushkina LO1 Gutner UA3, Shupik MA3, Maloshitskaya OA4, Lebedev AT4, Zateyshchikov DA1-2ġĜentral State Medical Academy of Department of Presidential Affairs, Moscow, RussiaĢĜity Clinical Hospital № 51, Moscow, Russiaģ Institute of Biochemical Physics named after N. CHANGES IN PLASMA SPHINGOLIPID LEVELS AGAINST THE BACKGROUND OF LIPID-LOWERING THERAPY IN PATIENTS WITH PREMATURE ATHEROSCLEROSIS
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |